Given its role in cancer progression, the MET receptor has become a target for therapeutic intervention. Several strategies have been developed to inhibit MET signaling, including small molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and HGF antagonists. Agents like crizotinib, capmatinib, and tepotinib are examples of MET inhibitors that have shown efficacy in clinical trials for MET-altered cancers.
